Medication info
Eviscure (Memantine Hydrochloride)

Eviscure (Memantine Hydrochloride)

Prescription medicationTabletOral
Ingredient · strength
Memantine Hydrochloride›10mg / 1 tablet
Manufacturer / importer
Lundbeck Korea Co., Ltd.
Appearance
Oval film-coated tablets that are light yellow to yellow, with a score line on both sides; one side is engraved with 'M' and the other side with '1, 0'.
Packaging
56 tablets (14 tablets/PTP × 4)
Approval status
Active

MFDS item code 200308324 · Approved 2003.09.18 · Insurance code 668000040

Summary

Main use
Treatment of moderate to severe Alzheimer's disease
Who takes it
Adults
Adult dose
This medicine is administered orally once daily at the same time each day. If necessary, it may be administered twice daily. It may be taken with or without food. 1. Adults Dose escalation: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows, until the maintenance dose is reached. Week 1 (Days 1–7) Administer 5mg once daily for 7 days. Week 2 (Days 8–14) Administer 10mg once daily for 7 days. Week 3 (Days 15–21) Administer 15mg once daily for 7 days. From Week 4 onward Administer 20mg once daily. Maintenance dose: The recommended maintenance dose is 20mg once daily. 2. Older adults: Based on clinical data, the recommended dose for patients aged 65 years or older is 20mg once daily. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance 30-49 mL/min), reduce the daily dose to 10mg. If well tolerated after at least 7 days of treatment, the dose may be increased to 20mg once daily according to the standard dose escalation method. In patients with severe renal impairment (creatinine clearance 5-29 mL/min), reduce the daily dose to 10mg. 4. Patients with hepatic impairment: No dose adjustment is necessary in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). Since no data are available on the use of memantine in patients with severe hepatic impairment, it is preferable not to administer this medicine.

Ingredients

Importer
Lundbeck Korea Co., Ltd.

Efficacy & effects

Treatment of moderate to severe Alzheimer's disease

  • Alzheimer's disease
View approved original text

This medication is used for the treatment of Alzheimer's disease in moderate to severe stages.

How to take

Adult dose

This medicine is administered orally once daily at the same time each day. If necessary, it may be administered twice daily. It may be taken with or without food. 1. Adults Dose escalation: The maximum daily dose is 20mg. To minimize the risk of adverse reactions, increase the dose by 5mg per week over the first 3 weeks as follows, until the maintenance dose is reached. Week 1 (Days 1–7) Administer 5mg once daily for 7 days. Week 2 (Days 8–14) Administer 10mg once daily for 7 days. Week 3 (Days 15–21) Administer 15mg once daily for 7 days. From Week 4 onward Administer 20mg once daily. Maintenance dose: The recommended maintenance dose is 20mg once daily. 2. Older adults: Based on clinical data, the recommended dose for patients aged 65 years or older is 20mg once daily. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild renal impairment (creatinine clearance: 50-80 mL/min). In patients with moderate renal impairment (creatinine clearance 30-49 mL/min), reduce the daily dose to 10mg. If well tolerated after at least 7 days of treatment, the dose may be increased to 20mg once daily according to the standard dose escalation method. In patients with severe renal impairment (creatinine clearance 5-29 mL/min), reduce the daily dose to 10mg. 4. Patients with hepatic impairment: No dose adjustment is necessary in patients with mild or moderate hepatic impairment (Child-Pugh A, Child-Pugh B). Since no data are available on the use of memantine in patients with severe hepatic impairment, it is preferable not to administer this medicine.

Precautions

This medication should not be used in patients who are allergic to the components of this drug. It should also not be administered to patients with severely impaired liver function or significantly reduced kidney function. Patients with epilepsy or a history of seizures should use this medication with special caution. Additionally, the potential for more severe side effects exists when used in conjunction with other drugs that have similar actions, hence they should not be used together. Patients with factors that change the acidity (pH) of urine should be cautious, and it should be administered carefully to patients with heart-related diseases or uncontrolled blood pressure. This medication may cause side effects such as dizziness, headaches, constipation, drowsiness, and hypertension, and rare cases of confusion or hallucination symptoms have also been reported. As there may be potential drug interactions, it is essential to inform healthcare providers of any medications being currently taken. Pregnant women or those who may become pregnant should consult a doctor before taking this medication, and breastfeeding should be discontinued if nursing. It is not used in children or adolescents under 18 years of age, as safety and efficacy have not been established. In the event of overdose, severe symptoms such as coma, hallucinations, and seizures may occur, and immediate medical attention is required in such cases. This medication may decrease the speed of patient response and attention, thus specific caution should be taken when driving or operating machinery. Lastly, this medication must be kept out of reach of children and it is safe to keep it in its original container without transferring it to another container.

Side effects

  • Dizziness
  • headache
  • constipation
  • drowsiness
  • hypertension
  • fungal infection
  • drug hypersensitivity reaction
  • confusion
  • hallucination
  • psychotic reaction
Show 19 more
  • balance disorder
  • gait disturbance
  • seizure
  • heart failure
  • venous thrombosis/ thrombosis embolism
  • shortness of breath
  • vomiting
  • pancreatitis
  • elevated liver function test values
  • hepatitis
  • fatigue
  • nonspecific fatigue
  • weakness
  • diarrhea
  • agitation
  • aggression
  • stupor
  • unconsciousness
  • double vision

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to avoid exposure to air and moisture. The storage temperature should be maintained between 1 and 30 degrees Celsius to ensure the medication's effectiveness.

Appearance and packaging

Appearance

Oval film-coated tablets that are light yellow to yellow, with a score line on both sides; one side is engraved with 'M' and the other side with '1, 0'.

Package unit

56 tablets (14 tablets/PTP × 4)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.